Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | INSR | P06213 | 1/20 | 0.31 |
| ▸ | ITK | Q08881 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4963473 | 0.90 | SMN1; SMN2 (0.41) | KMT2APDK2PDK4HPGDRAB9A | |
| SCHEMBL4964535 | 0.90 | PDK1 (0.35) | HSD11B1PDK1PDK2PDK3PDK4 | |
| SCHEMBL4963781 | 0.89 | CTNNB1 (0.35) | KMT2ABRD4PDK1PDK2PDK3 | |
| SCHEMBL4664854 | 0.88 | KMT2A (0.34) | KMT2AHSD11B1PDK1PDK2PDK3 | |
| SCHEMBL5108006 | 0.87 | CXCR3 (0.35) | KMT2ABRD4PDK1HPGDMEN1 | |
| SCHEMBL4663226 | 0.87 | KMT2A (0.33) | KMT2AHSD11B1PDK1PDK2PDK3 | |
| SCHEMBL4963749 | 0.87 | GSK3B (0.35) | KMT2AMEN1RAB9ADHODHALDH1A1 | |
| SCHEMBL4965054 | 0.87 | HCRTR1 (0.32) | BRD4 | |
| SCHEMBL4664629 | 0.86 | ALDH1A1 (0.41) | KMT2ABRD4HSD11B1GAAALDH1A1 | |
| SCHEMBL4666499 | 0.86 | CYP2C9 (0.37) | KMT2AHSD11B1PDK1PDK2PDK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | NYCOMED GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| US-20080113963-A1 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2008-05-15 | — | — | US | disclosed |
| EP-1904454-A2 | PROCESS FOR THE PRODUCTION OF INTERMADIATES FOR THE PREPARATION OF TRICYCLIC BENZIMIDAZOLES | Nycomed GmbH (DE) | 2008-04-02 | — | — | EP | disclosed |
| US-7307084-B2 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2007-12-11 | — | — | US | disclosed |
| WO-2006136552-A2 | PROCESS FOR THE PRODUCTION OF INTERMADIATES FOR THE PREPARATION OF TRICYCLIC BENZIMIDAZOLES | NYCOMED GMBH (DE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060194968-A1 | Cyclic benizimidazoles | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194968-A1 | Cyclic benizimidazoles | VIP, SI, GIPR | KMT2A 3220/4885BRD4 85/4885HSD11B1 967/4885 |
| US-20080113963-A1 | Cyclic benzimidazoles | VIP, GIPR, SI | KMT2A 4735/4885BRD4 1068/4885HSD11B1 2384/4885 |
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | CYP1B1, CYP1A1, CYP3A4 | KMT2A 2360/4885BRD4 366/4885HSD11B1 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.